The Glucose Ketone Index in Cancer Care

Introduction

Cancer is often discussed primarily as a genetic disease, but tumors also depend on metabolism. Many cancer cells consume large amounts of glucose and convert it into lactate even when oxygen is available, a pattern known as the Warburg effect. This altered glucose metabolism has led researchers to investigate whether lowering circulating glucose while increasing ketone production could create a less favorable metabolic environment for certain tumors.

The glucose ketone index, or GKI, was developed as a simple way to describe that metabolic state. It compares blood glucose with beta-hydroxybutyrate, the primary ketone measured in blood. A higher GKI generally reflects higher glucose relative to ketones, while a lower GKI reflects deeper nutritional ketosis combined with lower glucose availability.

Interest in GKI grew from research on ketogenic metabolic therapy, particularly in aggressive brain tumors such as glioblastoma. The original GKI paper published in 2015 proposed the index as a practical tool for monitoring the relationship between glucose and ketones during metabolic management of brain cancer. Since then, GKI has appeared in case reports, feasibility studies and early clinical trials examining ketogenic diets alongside conventional oncology care.

The underlying idea is more nuanced than the popular claim that sugar simply “feeds cancer.” Every human cell requires energy, and many healthy tissues also use glucose. Tumors differ greatly in their genetics, location, fuel use and ability to adapt. Some may depend heavily on glucose, while others can use fatty acids, amino acids or ketones under certain conditions. A lower GKI should therefore be understood as a measurement of the patient’s metabolic state—not proof that a tumor has been deprived of fuel.

Human evidence remains preliminary. A recent systematic review of ketogenic diets in malignant glioma found that ketosis was achievable, but GKI targets were rarely sustained and improvements in survival or quality of life remain unproven. Early studies support continued research, but GKI has not been validated as a universal cancer-treatment target, a measure of tumor response or a replacement for imaging, pathology and established oncology care.

In this article, we will examine how GKI is calculated, why researchers are studying it in cancer metabolism, what different values may indicate and where its limitations become clinically important. The goal is not to present ketosis as a cancer cure, but to explain how glucose and ketone monitoring may contribute to carefully supervised metabolic therapy used alongside—not instead of—standard cancer treatment.

🎧 Listen to the Episode:

Cancer cells often consume enormous amounts of glucose—but that doesn't mean eliminating dietary sugar can simply “starve” a tumor.

In this episode of The Health Pulse, we unpack the Warburg effect, ketogenic metabolic therapy, beta-hydroxybutyrate, and the Glucose Ketone Index (GKI) to explain what researchers are actually investigating. We also explore why extreme metabolic targets can become dangerous in people facing cancer, particularly when weight loss and cachexia are already concerns.

▶️ Click play below to listen, or keep reading to discover where the science of cancer metabolism ends—and where the internet hype begins.

What Is the Glucose Ketone Index?

The glucose ketone index is a ratio that compares the concentration of glucose in the blood with the concentration of beta-hydroxybutyrate, or BHB. It provides a snapshot of the balance between glucose availability and nutritional ketosis at a particular moment.

GKI should not be confused with the glycemic index used to rank carbohydrate-containing foods. The glycemic index predicts how strongly a food may raise blood glucose. The glucose ketone index uses actual blood measurements to describe a person’s current metabolic state.

Because glucose and ketones must be expressed in the same units, glucose reported in milligrams per deciliter must first be converted to millimoles per liter. The calculation is:

The converted glucose value is then divided by the blood ketone measurement:

For example, a person with a glucose level of 90 mg/dL and a BHB level of 1.0 mmol/L would calculate the index as follows:

If the same person’s BHB increased to 2.0 mmol/L while glucose remained at 90 mg/dL, the GKI would fall to 2.5. The lower result reflects a greater concentration of ketones relative to glucose. It does not prove that a tumor is shrinking or that cancer cells are unable to access energy.

Both measurements should be taken at approximately the same time. Blood BHB is preferred over urine ketone strips because urine acetoacetate reflects ketones that have already been excreted and becomes less reliable as the body adapts to ketosis. Breath acetone can document ketosis but is not interchangeable with blood BHB in the original GKI calculation.

Timing also matters. Meals, exercise, sleep, stress, corticosteroids, infection and cancer treatments can change glucose or ketone levels. A single GKI result may therefore be less informative than a trend measured under similar conditions.

GKI is a monitoring tool rather than a diagnostic test. It cannot detect cancer, identify tumor type, determine cancer stage or replace scans and laboratory assessments used by an oncology team.

Key takeaway: GKI is calculated by converting glucose to mmol/L and dividing it by blood beta-hydroxybutyrate. It describes the balance between glucose and ketones, but it does not directly measure tumor activity or treatment response.

Introduction

The scientific interest in GKI begins with the way many tumors process energy. Healthy cells typically use mitochondrial respiration to produce most of their ATP when oxygen is available. Many cancer cells, however, consume unusually large amounts of glucose and convert much of it into lactate, even in the presence of oxygen. This metabolic pattern is known as aerobic glycolysis or the Warburg effect.

Aerobic glycolysis is less efficient at producing ATP from each molecule of glucose, but it can support rapid growth by supplying intermediates needed to manufacture nucleotides, amino acids and cell membranes. Increased glucose uptake is so common in many cancers that PET imaging uses a radioactive glucose analogue to locate metabolically active tumors.

Lowering blood glucose may reduce one source of fuel and growth-related signaling available to glucose-dependent tumors. Lower glucose can also reduce circulating insulin, which may influence pathways connected with cell growth, nutrient sensing and survival. These changes are among the reasons ketogenic diets, fasting strategies and other metabolic interventions are being studied alongside conventional cancer treatment.

Ketosis creates another metabolic change. As insulin falls and fatty acids are released, the liver produces ketone bodies, including beta-hydroxybutyrate. Many healthy tissues can adapt to using ketones for energy. Some researchers propose that certain cancer cells may have less metabolic flexibility because of mitochondrial abnormalities or reduced capacity to oxidize ketones efficiently.

However, this limitation is not shared by every cancer. Tumors are metabolically diverse, and cancer cells can evolve or use alternative fuels such as glutamine, fatty acids and lactate. Some tumors may even oxidize ketones under particular conditions. The claim that cancer cells are universally unable to use ketones is therefore too broad.

GKI was created to track glucose and ketosis together rather than focusing on either measurement independently. Glucose can remain elevated despite measurable ketones, particularly during corticosteroid treatment, physiological stress or poorly controlled diabetes. Ketones can also be low while glucose is relatively normal. The ratio provides a clearer description of the combined metabolic environment.

Preclinical studies suggest that lowering glucose while elevating ketones may slow the growth of selected tumors or enhance sensitivity to radiation and other treatments. Human studies have shown that supervised ketogenic diets can often produce ketosis, but whether achieving a particular GKI improves survival remains uncertain. The latest systematic review of ketogenic diets in malignant glioma found inconsistent survival results and noted that GKI was rarely reported or consistently maintained.

GKI is therefore best understood as a metabolic monitoring variable within an experimental or carefully supervised supportive strategy. It describes whether the intended glucose-ketone state has been achieved, but it cannot establish that the state is controlling the cancer.

Key takeaway: Researchers study GKI because it captures two simultaneous metabolic changes—lower glucose availability and higher ketone production. These changes may affect some tumors, but cancer metabolism is diverse, and no specific GKI has been proven to control cancer in humans.

Is There a Therapeutic GKI?

GKI charts often divide results into categories such as mild ketosis, moderate ketosis and therapeutic ketosis. These categories can be useful for describing the depth of ketosis, but they should not be mistaken for clinically established cancer-treatment thresholds.

The original 2015 GKI publication proposed that a value between approximately 1 and 2 might represent a “zone of metabolic management” for brain cancer, with values approaching 1 considered potentially more therapeutic. This proposal was based primarily on animal experiments and a small number of human case reports—not large randomized clinical trials.

Achieving a GKI of 1 requires glucose and ketones to be present at approximately equal concentrations in mmol/L. For example, a glucose level of 72 mg/dL converts to 4.0 mmol/L. Reaching a GKI of 1 at that glucose level would require a BHB concentration of approximately 4.0 mmol/L. This degree of ketosis is difficult to maintain through an unrestricted ketogenic diet and may occur more readily during prolonged fasting, calorie restriction or highly structured therapeutic protocols.

Some clinical studies have used less aggressive targets. A 2026 trial of intensive ketogenic metabolic therapy in glioblastoma selected a mean daily GKI of 6 or lower as its feasibility target. Most participants achieved that goal, and those who completed the protocol reached substantially lower average values. However, the study was small, nonrandomized and compared outcomes with contemporary controls, so it cannot establish that lowering GKI caused the reported survival difference.

A recent systematic review reached a more cautious conclusion. Across 23 glioma studies involving 306 patients, GKI was reported infrequently, and proposed targets were rarely achieved outside fasting periods. Randomized trials did not demonstrate significant improvements in overall or progression-free survival. The available evidence therefore does not identify a universal GKI target that has been proven to slow tumor growth or improve survival.

The appropriate metabolic state may also differ by tumor type, treatment, nutritional status and individual tolerance. A value proposed for glioblastoma cannot automatically be applied to breast, colorectal, prostate or pancreatic cancer. Tumors within the same category may also differ substantially in their glucose dependence and ability to use alternative fuels.

Lower is not always better. Aggressively pursuing a very low GKI can lead to inadequate calorie or protein intake, weight loss, loss of muscle mass, dehydration, electrolyte disturbances or hypoglycemia. These risks are especially important for people experiencing cancer-related cachexia, nausea, difficulty swallowing or treatment-related loss of appetite.

GKI should therefore be treated as a descriptive metabolic marker rather than a therapeutic endpoint. If it is used during cancer care, the target and monitoring plan should be established with the oncology team and a dietitian experienced in ketogenic therapy.

Key takeaway: Values near 1 were proposed as potentially therapeutic in early brain-cancer research, but no GKI range has been clinically validated as a universal cancer-treatment target. The safest and most useful target depends on the individual, the tumor and the treatment plan.

How to Measure GKI Reliably

GKI can change considerably throughout the day, so consistent measurement is more informative than checking at random times. Glucose and beta-hydroxybutyrate should be measured within a few minutes of each other using a blood glucose and ketone meter capable of measuring both values.

The original GKI researchers suggested measuring approximately two to three hours after a meal, when the immediate glucose response has begun to settle. Some protocols also include a fasting morning measurement. Either approach can be useful, but results should be compared with measurements taken under similar conditions.

Morning readings may be affected by the dawn phenomenon. Cortisol and other counter-regulatory hormones rise before waking and stimulate the liver to release glucose. This can temporarily increase GKI even when carbohydrate intake is very low. Poor sleep, emotional stress and pain may produce similar changes.

Meals alter both sides of the calculation. Carbohydrate generally raises glucose and suppresses ketone production, increasing GKI. Protein can also stimulate insulin and reduce ketones temporarily, although the response varies with the amount consumed and the person’s metabolic health. Dietary fat usually has a smaller immediate effect on glucose but does not guarantee that blood ketones will rise.

Exercise creates another source of variation. High-intensity activity can temporarily raise glucose because adrenaline signals the liver to release stored glycogen. Longer-duration aerobic exercise may lower glucose and increase ketone production later. Measuring immediately after exercise may therefore produce a result that does not represent the person’s usual metabolic state.

Cancer treatment can have an even greater effect. Corticosteroids such as dexamethasone are frequently used to reduce inflammation, control nausea or relieve cerebral edema. They can raise glucose, increase insulin resistance and make a low GKI difficult to achieve. Surgery, infection, radiation, chemotherapy and the physiological stress of cancer itself may also alter glucose metabolism.

Hydration, meter accuracy and testing technique matter as well. Residue from food or lotion on the hands can distort a finger-stick glucose reading. Hands should be washed and dried thoroughly before testing, and the meter should be used according to the manufacturer’s instructions. Blood BHB should be measured rather than relying on urine ketone strips.

A single low GKI should not be interpreted as a treatment success, and a temporary increase should not be treated as evidence that therapy has failed. Trends collected under consistent conditions provide a more meaningful picture. These measurements should also be reviewed alongside weight, food intake, muscle mass, symptoms, medication use and conventional cancer assessments.

Key takeaway: Reliable GKI monitoring requires paired blood glucose and BHB measurements taken under similar conditions. Meals, exercise, sleep, stress, corticosteroids and cancer treatment can all change the result, making trends more meaningful than isolated readings.

What Human Research Shows

The biological rationale for ketogenic metabolic therapy is compelling, but clinical evidence in people with cancer remains limited. Most published studies are small, use different dietary protocols and include patients with different tumor types, stages and treatments. This makes it difficult to determine whether changes in glucose, ketones or GKI improve cancer outcomes.

The strongest evidence supports feasibility rather than efficacy. Supervised ketogenic diets can lower carbohydrate intake, produce nutritional ketosis and reduce GKI in at least some patients. Most reported adverse effects are mild and include constipation, fatigue, nausea, headache and temporary symptoms during adaptation. Adherence remains a major challenge, particularly during chemotherapy or radiation.

A 2025 phase 1 trial studied a supervised ketogenic diet alongside standard chemoradiation in patients with newly diagnosed glioblastoma. The primary objective was safety and feasibility, not whether the diet extended survival. Participants monitored glucose and ketones twice daily, demonstrating that intensive metabolic tracking could be incorporated into standard treatment under clinical supervision.

A more intensive 2026 glioblastoma study combined a ketogenic diet, time-restricted eating, prolonged fasting and exercise with standard oncology care. Most participants maintained the study’s GKI target, and the intervention was associated with encouraging survival and quality-of-life findings. However, only 18 patients began the metabolic intervention, there was no randomized control group, and several components were used simultaneously. The results are promising but cannot determine whether GKI reduction itself produced the apparent benefit.

The broader evidence remains uncertain. A 2026 systematic review of ketogenic diets in malignant glioma included 23 studies and 306 patients. Only two were randomized trials. Ketosis was generally achievable, but survival outcomes were inconsistent, and the randomized studies did not show significant improvements in overall or progression-free survival. GKI was rarely reported, and target values were difficult to sustain.

Research outside brain cancer is even more heterogeneous. Studies have included people with breast, ovarian, endometrial, prostate, pancreatic, colorectal and advanced mixed cancers. Some report improvements in glucose, insulin, triglycerides, body composition or quality of life, but evidence that ketogenic diets slow tumor progression or extend survival remains inconclusive.

Weight loss is a particularly important concern. Meta-analyses have found that ketogenic diets can reduce body weight and fat mass in cancer patients. This may benefit someone with obesity and insulin resistance but could be harmful to a person already experiencing involuntary weight loss, sarcopenia or cachexia. The same dietary intervention can therefore have very different consequences depending on the patient.

Current research does not support using GKI to determine whether chemotherapy is working, whether a tumor is growing or whether conventional treatment can be stopped. Those questions still require pathology, imaging, established tumor markers and evaluation by the oncology team.

Key takeaway: Human studies show that supervised ketogenic diets and GKI monitoring are feasible for some cancer patients, but evidence that a specific GKI improves tumor control or survival remains insufficient. Most positive findings come from small or nonrandomized studies that require confirmation.

Safety Comes Before a Lower GKI

Pursuing a lower GKI is not appropriate for every person with cancer. The potential risks of carbohydrate restriction, fasting and weight loss must be considered alongside the experimental metabolic rationale. In many patients, maintaining strength, muscle mass and treatment tolerance is more important than reaching a particular glucose-ketone ratio.

Cancer cachexia is one of the greatest concerns. This syndrome causes involuntary loss of skeletal muscle and body fat and cannot be reversed simply by increasing calorie intake. The National Cancer Institute emphasizes that early detection of weight and muscle loss is essential because cachexia becomes increasingly difficult to treat as it progresses.

A restrictive ketogenic diet may worsen nutritional risk when a person already has poor appetite, nausea, vomiting, mouth sores, difficulty swallowing or early fullness. Patients with pancreatic, esophageal, stomach, head and neck, lung or other advanced cancers may be particularly vulnerable to inadequate calorie and protein intake. In these situations, a lower GKI may reflect worsening malnutrition rather than a beneficial metabolic state.

Diabetes medications create additional risks. Insulin and sulfonylureas can cause hypoglycemia when carbohydrate intake falls rapidly. Medication doses may need to be adjusted by the prescribing clinician before dietary changes begin—not after low glucose develops.

SGLT2 inhibitors require special caution. Medications such as empagliflozin, dapagliflozin and canagliflozin increase urinary glucose loss and can promote ketone production. Combining them with fasting or a ketogenic diet may increase the risk of euglycemic diabetic ketoacidosis, a dangerous condition that can occur even when glucose is not dramatically elevated. These medications should never be stopped or adjusted without guidance from the prescribing clinician.

People with type 1 diabetes should not attempt to lower GKI independently. Ketones caused by nutritional ketosis are not the same as diabetic ketoacidosis, but insulin deficiency can turn rising ketones into a medical emergency. GKI was not designed to distinguish safe ketosis from ketoacidosis.

Additional caution is warranted for people with significant kidney, liver, pancreatic or gallbladder disease; a history of eating disorders; pregnancy or breastfeeding; electrolyte abnormalities; or medications that affect glucose, hydration and blood pressure. Treatment-specific factors must also be considered by the oncology team.

Monitoring should extend beyond glucose and ketones. Body weight, food intake, muscle strength, kidney and liver function, electrolytes, symptoms and medication requirements may be more important indicators of safety. A registered dietitian experienced in oncology and ketogenic therapy can help preserve adequate protein, calories and micronutrients.

Urgent medical evaluation is necessary when elevated ketones occur with persistent vomiting, abdominal pain, rapid breathing, confusion, severe weakness or dehydration. A numerically low GKI is never desirable when it results from dangerous hypoglycemia, ketoacidosis or inadequate nutrition.

Key takeaway: A lower GKI is not automatically healthier or more therapeutic. Cancer-related weight loss, cachexia, diabetes medications and treatment side effects can make aggressive ketosis dangerous, so metabolic interventions require oncology and nutrition supervision.

What Should Be Monitored Alongside GKI?

GKI provides only two measurements: glucose and beta-hydroxybutyrate. It does not show whether a patient is adequately nourished, tolerating treatment or maintaining organ function. A safe metabolic-therapy plan requires a broader assessment.

A comprehensive metabolic panel helps monitor glucose, electrolytes, kidney function and liver-related markers. Sodium, potassium and bicarbonate deserve attention during ketogenic diets or fasting because lower insulin levels can increase fluid and sodium loss. Vomiting, diarrhea and reduced food intake during cancer treatment can intensify these changes.

Kidney function is particularly important when protein intake, hydration or medications change. Creatinine and estimated glomerular filtration rate help evaluate filtration, although creatinine may appear deceptively low when a patient is losing muscle. Results should be interpreted alongside weight, body composition and clinical status.

Liver testing provides information about AST, ALT, alkaline phosphatase, bilirubin and albumin. These values may change because of the cancer, medications, treatment toxicity, infection, inadequate nutrition or preexisting liver disease. An abnormal result should not automatically be attributed to the ketogenic diet or the cancer without evaluation.

A complete blood count remains essential during oncology treatment. Hemoglobin, white blood cells and platelets can be affected by chemotherapy, radiation, bleeding, nutritional deficiencies or bone marrow involvement. GKI cannot reveal any of these complications.

Hemoglobin A1c, fasting glucose and fasting insulin can help describe longer-term glucose regulation, although A1c may become less reliable after blood transfusion, anemia or changes in red blood cell survival. Corticosteroid use should also be documented because it can substantially increase glucose and insulin requirements.

A lipid panel may be useful before and during a long-term ketogenic diet. Some people experience reductions in triglycerides, while others develop increases in LDL-C or ApoB. These changes may be less urgent than the cancer itself, but they still deserve interpretation within the person’s prognosis, cardiovascular history and treatment plan.

Nutritional assessment cannot rely on albumin alone. Albumin is influenced by inflammation, hydration, liver function and illness severity. Weight trend, dietary intake, muscle strength, physical function and body composition provide more useful context for identifying malnutrition and sarcopenia.

GKI should also never replace established cancer monitoring. Imaging, pathology, clinical examination and appropriately selected tumor markers remain the tools used to evaluate disease response. A falling GKI with a growing tumor is not a successful treatment response.

QuickLab Mobile can support patients in Miami with convenient at-home collection for glucose, comprehensive metabolic panels, complete blood counts, hemoglobin A1c, fasting insulin, lipid testing and other markers requested by their healthcare team. Blood ketone measurements used for daily GKI tracking are typically performed with a home BHB meter.

Key takeaway: Safe GKI monitoring requires more than glucose and ketones. Electrolytes, kidney and liver function, blood counts, metabolic markers, weight and muscle status help determine whether the intervention is safe, while imaging and oncology assessments determine whether the cancer is responding.

Conclusion

The glucose ketone index provides a simple way to describe the relationship between circulating glucose and beta-hydroxybutyrate. It can confirm whether a ketogenic diet, fasting strategy or other metabolic intervention is producing the intended shift toward lower glucose availability and greater nutritional ketosis.

That information has made GKI useful in early research, particularly in glioblastoma and other brain tumors. However, the index remains a metabolic monitoring tool—not a cancer test, tumor marker or validated measure of treatment response. A lower result does not prove that a tumor is being deprived of energy, and no universal GKI target has been shown to improve survival across cancer types.

Cancer metabolism is heterogeneous. Some tumors depend heavily on glucose, while others can adapt and use alternative fuels. The effects of metabolic therapy may also vary with cancer type, stage, medications, nutritional status and standard treatment. Findings from animal studies or individual case reports cannot automatically be applied to every patient.

Safety must remain the priority. Aggressive carbohydrate restriction or fasting can be dangerous when a person is experiencing cachexia, muscle loss, poor appetite, treatment-related nausea or medication-induced changes in glucose. The objective should never be to achieve the lowest possible GKI at the expense of strength, hydration, protein intake or the ability to tolerate treatment.

When used, GKI should be part of a supervised plan developed with the oncology team and an experienced dietitian. It may complement standard care by documenting metabolic changes, but it should never replace surgery, radiation, chemotherapy, immunotherapy, targeted therapy or other evidence-based cancer treatments.

QuickLab Mobile offers at-home blood collection in Miami for glucose regulation, fasting insulin, blood counts, kidney and liver function, electrolytes and other markers that may support safe metabolic monitoring. Testing should be ordered and interpreted within the patient’s complete oncology and nutrition plan.

👉 Need a specimen collection?. Book Now

Disclaimer:

The information provided in this blog, podcast, and associated content is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. The content shared is based on reputable sources, medical literature, and expert insights, but it should not be used as a replacement for direct consultation with a licensed healthcare provider.

No Doctor-Patient Relationship: Engaging with this content does not create a doctor-patient relationship between you and QuickLabMobile or any contributors. Always consult with a qualified physician, specialist, or healthcare professional before making any medical decisions, changing your treatment plan, or starting/stopping any medications.

Not a Substitute for Medical Advice: While we strive to provide accurate and up-to-date information, medicine is constantly evolving. New research, treatments, and medical recommendations may emerge, and individual health conditions can vary. Do not rely solely on this content for health decisions. If you are experiencing symptoms, have concerns about your health, or require medical assistance, seek immediate care from a licensed medical professional.

Emergency Situations: If you are experiencing a medical emergency, such as difficulty breathing, chest pain, signs of a stroke, or any other life-threatening condition, call 911 (or your local emergency services) immediately. Do not delay seeking emergency care based on information provided here.

Liability Disclaimer: QuickLabMobile, its contributors, and any associated entities do not assume liability for any damages, harm, or adverse outcomes resulting from the use, interpretation, or misuse of the information provided in this content. You are responsible for your own healthcare decisions and should always verify information with a trusted medical professional.

External Links & References: This content may include links to external sources, medical studies, or third-party websites for further reading. These links are provided for convenience and informational purposes only. QuickLabMobile does not endorse, control, or take responsibility for the accuracy of external content. Always verify information with authoritative sources such as the CDC, NIH, WHO.

Final Note: Your health is unique, and what works for one person may not be suitable for another. Stay informed, ask questions, and always prioritize professional medical guidance